Overview

A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-

Status:
Completed

Trial end date:
2017-02-10

Target enrollment:

Participant gender:

Summary

The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with DE-117 ophthalmic solution is non-inferior to latanoprost ophthalmic solution 0.005%.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Santen Pharmaceutical Co., Ltd.

Treatments:

Latanoprost
Ophthalmic Solutions
Pharmaceutical Solutions